Results 61 to 70 of about 10,615 (182)
OX1 and OX2 orexin/hypocretin receptor pharmacogenetics [PDF]
Orexin/hypocretin peptide mutations are rare in humans. Even though human narcolepsy is associated with orexin deficiency, this is only extremely rarely due to mutations in the gene coding prepro-orexin, the precursor for both orexin peptides. In contrast, coding and non-coding variants of the OX1 and OX2 orexin receptors have been identified in many ...
Miles Douglas Thompson +5 more
openaire +4 more sources
ABSTRACT Background Falls are the leading cause of injury in older adults. Sedative‐hypnotic use is a known risk factor, but their use for insomnia continues to be common. Dual orexin receptor antagonists (DORAs) are a new, potentially safer class of medications for insomnia.
Arianna Paolone +5 more
wiley +1 more source
Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z‐Drugs: A Target Trial Emulation
ABSTRACT Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z‐drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study
Yuichiro Matsuo +5 more
wiley +1 more source
Summary The world‐wide prevalence of insomnia disorder reaches up to 10% of the adult population. Women are more often afflicted than men, and insomnia disorder is a risk factor for somatic and mental illness, especially depression and anxiety disorders.
Dieter Riemann +13 more
wiley +1 more source
SB‐334867‐A: the first selective orexin‐1 receptor antagonist [PDF]
The pharmacology of various peptide and non‐peptide ligands was studied in Chinese hamster ovary (CHO) cells stably expressing human orexin‐1 (OX1) or orexin‐2 (OX2) receptors by measuring intracellular calcium ([Ca2+]i) using Fluo‐3AM. Orexin‐A and orexin‐B increased [Ca2+]i in CHO‐OX1 (pEC50=8.38±0.04 and 7.26±0.05 respectively, n=12) and CHO‐OX2 ...
D, Smart +6 more
openaire +2 more sources
Narcolepsy and rapid eye movement sleep
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini +4 more
wiley +1 more source
Role of orexin receptors in histamine- and chloroquine-induced pruriceptive processing
It is known that orexin peptides are involved in nociceptive processing, while little is known about the roles of these peptides in itch processing. To reveal the functions of orexin peptides in pruriceptive processing, orexin A (OX-A) and orexin B (OX-B)
Anna Kanemaru-Kawazoe +7 more
doaj +1 more source
Ageing‐related modification of sleep and breathing in orexin‐knockout narcoleptic mice
Summary Narcolepsy type‐1 (NT1) is a lifelong sleep disease, characterised by impairment of the orexinergic system, with a typical onset during adolescence and young adulthood. Since the wake–sleep cycle physiologically changes with ageing, this study aims to compare sleep patterns between orexin‐knockout (KO) and wild type (WT) control mice at ...
Stefano Bastianini +7 more
wiley +1 more source
Orexin receptor antagonists are on the market or under development for the treatment of insomnia and a number of other neuropsychiatric disorders. Currently, suvorexant, lemborexant and daridorexant, three dual orexin receptor antagonists (DORAs) have ...
Daniel Hoyer, Laura H. Jacobson
doaj +1 more source
Post-traumatic stress disorder (PTSD) is a prevalent condition affecting approximately 8% of the United States population and 20% of United States combat veterans. In addition to core symptoms of the disorder, up to 64% of individuals diagnosed with PTSD
Hannah B. Reiley +3 more
doaj +1 more source

